Orchestrated metal-coordinated carrier-free celastrol hydrogel intensifies T cell activation and regulates response to immune checkpoint blockade for synergistic chemo-immunotherapy

被引:6
作者
Wu, Linying [1 ]
Pi, Wenmin [1 ]
Huang, Xuemei [1 ]
Yang, Luping [1 ]
Zhang, Xiang [1 ]
Lu, Jihui [1 ]
Yao, Shuchang [1 ]
Lin, Xiaoyu [1 ]
Tan, Xinru [1 ]
Wang, Zhixia [1 ]
Wang, Penglong [1 ]
机构
[1] Beijing Univ Chinese Med, Sch Chinese Pharm, Beijing 102488, Peoples R China
基金
中国国家自然科学基金;
关键词
Carrier free small molecule hydrogel; Celastrol; Chemo-immunotherapy; Immune regulation; Tumor microenvironment; Cuproptosis; PD-1; BLOCKADE; NATURAL-PRODUCTS; CANCER; CHEMOTHERAPY; NANOPARTICLES; COMBINATION; RESISTANCE; INHIBITORS; MUTATIONS; HALLMARKS;
D O I
10.1016/j.biomaterials.2024.122723
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The challenges generated by insufficient T cell activation and infiltration have constrained the application of immunotherapy. Making matters worse, the complex tumor microenvironment (TME), resistance to apoptosis collectively poses obstacles for cancer treatment. The carrier-free small molecular self-assembly strategy is a current research hotspot to overcome these challenges. This strategy can transform multiple functional agents into sustain-released hydrogel without the addition of any excipients. Herein, a coordination and hydrogen bond mediated tricomponent hydrogel (Cel hydrogel) composed of glycyrrhizic acid (GA), copper ions (Cu2+) and celastrol (Cel) was initially constructed. The hydrogel can regulate TME by chemo-dynamic therapy (CDT), which increases reactive oxygen species (ROS) in conjunction with GA and Cel, synergistically expediting cellular apoptosis. What's more, copper induced cuproptosis also contributes to the anti-tumor effect. In terms of regulating immunity, ROS generated by Cel hydrogel can polarize tumor-associated macrophages (TAMs) into M1-TAMs, Cel can induce T cell proliferation as well as activate DC mediated antigen presentation, which subsequently induce T cell proliferation, elevate T cell infiltration and enhance the specific killing of tumor cells, along with the upregulation of PD-L1 expression. Upon co-administration with aPD-L1, this synergy mitigated both primary and metastasis tumors, showing promising clinical translational value.
引用
收藏
页数:16
相关论文
共 53 条
  • [1] Bioactive natural products in cancer prevention and therapy: Progress and promise
    Bishayee, Anupam
    Sethi, Gautam
    [J]. SEMINARS IN CANCER BIOLOGY, 2016, 40-41 : 1 - 3
  • [2] Elements of cancer immunity and the cancer-immune set point
    Chen, Daniel S.
    Mellman, Ira
    [J]. NATURE, 2017, 541 (7637) : 321 - 330
  • [3] Self-delivery biomedicine for enhanced photodynamic therapy by feedback promotion of tumor autophagy
    Chen, Shao-Yi
    Zhao, Lin -Ping
    Chen, Zu-Xiao
    Huang, Chu-Yu
    Kong, Ren-Jiang
    Wang, Yu-Qing
    Zhang, Da -Wei
    Li, Shi-Ying
    Ti, Hui -Hui
    Cheng, Hong
    [J]. ACTA BIOMATERIALIA, 2023, 158 : 599 - 610
  • [4] Hypoxia-responsive immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy for potentiating cancer immunotherapy
    Chen, Weiguo
    Sheng, Ping
    Chen, Yujiang
    Liang, Yi
    Wu, Sixin
    Jia, Liying
    He, Xin
    Zhang, Chunfeng
    Wang, Chongzhi
    Yuan, Chunsu
    [J]. CHEMICAL ENGINEERING JOURNAL, 2023, 451
  • [5] Immune Exosomes Loading Self-Assembled Nanomicelles Traverse the Blood-Brain Barrier for Chemo-immunotherapy against Glioblastoma
    Cui, Jiwei
    Wang, Xue
    Li, Jinge
    Zhu, Anran
    Guo, Yumiao
    Di, Liuqing
    Wang, Ruoning
    [J]. ACS NANO, 2023, 17 (02) : 1464 - 1484
  • [6] Natural Proteasome Inhibitor Celastrol Suppresses Androgen-Independent Prostate Cancer Progression by Modulating Apoptotic Proteins and NF-kappaB
    Dai, Yao
    DeSano, Jeffrey
    Tang, Wenhua
    Meng, Xiaojie
    Meng, Yang
    Burstein, Ezra
    Lawrence, Theodore S.
    Xu, Liang
    [J]. PLOS ONE, 2010, 5 (12): : 1 - 9
  • [7] Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
    Davar, Diwakar
    Wang, Hong
    Chauvin, Joe-Marc
    Pagliano, Ornella
    Fourcade, Julien J.
    Ka, Mignane
    Menna, Carmine
    Rose, Amy
    Sander, Cindy
    Borhani, Amir A.
    Karunamurthy, Arivarasan
    Tarhini, Ahmad A.
    Tawbi, Hussein A.
    Zhao, Qing
    Moreno, Blanca H.
    Ebbinghaus, Scott
    Ibrahim, Nageatte
    Kirkwood, John M.
    Zarour, Hassane M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (35) : 3450 - +
  • [8] Dendritic cell subsets in cancer immunity and tumor antigen sensing
    Del Prete, Annalisa
    Salvi, Valentina
    Soriani, Alessandra
    Laffranchi, Mattia
    Sozio, Francesca
    Bosisio, Daniela
    Sozzani, Silvano
    [J]. CELLULAR & MOLECULAR IMMUNOLOGY, 2023, 20 (05) : 432 - 447
  • [9] Emerging role of natural products in cancer immunotherapy
    Dong, Songtao
    Guo, Xiangnan
    Han, Fei
    He, Zhonggui
    Wang, Yongjun
    [J]. ACTA PHARMACEUTICA SINICA B, 2022, 12 (03) : 1163 - 1185
  • [10] PD-L1 as a biomarker of response to immune-checkpoint inhibitors
    Doroshow, Deborah Blythe
    Bhalla, Sheena
    Beasley, Mary Beth
    Sholl, Lynette M.
    Kerr, Keith M.
    Gnjatic, Sacha
    Wistuba, Ignacio I.
    Rimm, David L.
    Tsao, Ming Sound
    Hirsch, Fred R.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (06) : 345 - 362